Boehringer Ingelheim And OSE Immunotherapeutics Enter Immuno-Oncology Partnership

05:00 EDT 5 Apr 2018 | Pharmaceutical Processing

News
Boehringer Ingelheim and OSE Immunotherapeutics enter into a global license and collaboration agreement in immuno-oncology to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells.
Contributed Author: 
Boehringer Ingelheim and OSE Immunotherapeutics
Topics: 
Operations

Original Article: Boehringer Ingelheim And OSE Immunotherapeutics Enter Immuno-Oncology Partnership

More From BioPortfolio on "Boehringer Ingelheim And OSE Immunotherapeutics Enter Immuno-Oncology Partnership"